Loading organizations...
§ Venture Capital · New York City, NY, USA
Healthcare private equity and venture capital firm investing in healthcare companies and connecting entrepreneurs with strategic partners.
Key people at Cathay Health.
Cathay Health is the Paris-based healthcare-focused venture capital and private equity investment arm of Cathay Capital that provides funding to life sciences and health technology startups. The firm focuses on cross-border investments across North America, Europe, and Asia, connecting entrepreneurs with strategic corporate partners to scale their operations across international markets. Operating as a specialized vehicle within its parent organization's broader $5 billion asset management platform, the health division manages a dedicated €500 million venture fund. The firm is backed by major institutional investors and multinational healthcare corporations, including strategic partnerships with industry leaders such as Sanofi and bioMérieux. Its investment portfolio features emerging medical technology, biopharmaceutical, and digital health companies, including the artificial intelligence company Owkin. Cathay Health was established in 2021 as a specialized investment division under the leadership of Cathay Capital founder Mingpo Cai.
Key people at Cathay Health.
Cathay Health is a global venture capital firm focused on investing in companies at the intersection of life sciences, healthcare, and technology, aiming to generate positive impacts on human health. It targets innovative, tech-enabled companies across sectors such as life science tools, diagnostics, clinical trial innovation, advanced therapeutics, new care models, and next-generation medical devices and materials. Operating from hubs including San Francisco, New York, London, Paris, and Basel, Cathay Health supports companies from venture to growth stages across Europe, North America, and Asia, fostering cross-border collaboration to accelerate advances in medicine and improve patient care worldwide[1][2][4].
Founded in 2021 as part of Cathay Capital, Cathay Health was established to leverage deep expertise in healthcare and technology to back transformative companies. Key partners include Hongjie Hu, co-founder and managing partner, who emphasizes the firm’s commitment to data-driven medicine and scalable health solutions. The firm’s evolution reflects a strategic focus on tech-enabled healthcare innovation, supported by a €500 million fund launched with backing from major investors like Bpifrance, AXA, and Groupe Pierre Fabre. Early investments include companies such as Tissium (biodegradable surgical sealants), Kojin Therapeutics (pre-clinical biotech), and healthcare venture studios, highlighting its broad yet specialized portfolio[3][4].
Cathay Health rides the wave of digital transformation in healthcare, where data-driven medicine, advanced therapeutics, and innovative medical devices are reshaping patient care. The timing is critical as healthcare systems worldwide seek cost-effective, personalized, and scalable solutions. Market forces such as aging populations, rising chronic diseases, and technological breakthroughs in gene and cell therapies create fertile ground for Cathay Health’s investments. By fostering innovation across continents, Cathay Health influences the global health ecosystem, enabling startups to access new markets and accelerate the adoption of cutting-edge medical technologies[1][2][4].
Looking ahead, Cathay Health is poised to deepen its impact by continuing to invest in breakthrough health technologies that address unmet clinical needs and improve healthcare delivery. Trends such as AI in diagnostics, personalized medicine, and advanced manufacturing for cell and gene therapies will likely shape its portfolio evolution. As healthcare increasingly integrates technology and data, Cathay Health’s role as a transatlantic connector and enabler of innovation will grow, potentially positioning it as a key player in shaping the future health economy globally[1][4].
